Long-Acting Risperidone Microspheres
Schizophrenia, Paranoid
Hospital Authority, Hong KongSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Schizophrenia, Paranoid cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Asenapine Organon and Co | Phase 3 | BB |
mk0249 Merck Sharp & Dohme LLC | Phase 2 | B |
SPIRO(CYCLOHEXANE-1,3'(1'H)-FURO(3,4-C)PYRIDINE)-4-CARBOXAMIDE, N-(1-(2-FLUOROPHENYL)-1H-PYRAZOL-3-YL)-1'-OXO-, TRANS- Merck Sharp & Dohme LLC | Phase 2 | B |
Same molecule, other indications
Long-Acting Risperidone Microspheres is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →